Two dosage interferon-α2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: A randomized trial

Haematologica

Volumn 83, Issue 1, 1998, Pages 40-47

  Offidani, Massimo ^a   Olivieri, Attilio ^a   Montillo, Marco ^a   Rupoli, Serena ^a   Centurioni, Riccardo ^a   Alesiani, Francesco ^a   Marchegiani, Gabriele ^a   Pieroni, Stefano ^a   Catarini, Massimo ^a   Pelliccia, Gennaro ^a   Altilia, Filippo ^a   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Interferon; Maintenance therapy; Multiple myeloma; Survival

Indexed keywords

ALBUMIN; ALPHA2B INTERFERON; BETA 2 MICROGLOBULIN; BIOLOGICAL RESPONSE MODIFIER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUTROPENIA; PLASMA CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0031907880     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma: new biological insights and advances in therapy. Blood 1989; 73:865-79.
2. Alexanian R, Haut A, Khan AU, et al. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208:1680-5.
3. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-42.
4. Pileri A, Palumbo A, Boccadoro M. Current therapeutic options for multiple myeloma. Haematologica 1996; 81:291-4.
5. Harley JB, Pajak TF, McIntyre OR, et al. Improved survival of increased risk myeloma patients on combined triple alkilating agent therapy: a study of CALGB. Blood 1979; 54:13-22.
6. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9:444-8.
7. Clavio M, Casciaro S, Gatti AM, et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996; 81:238-44.
8. Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myelomatosis. Lancet 1979; i:245-7.
9. Ahre A, Bjorkholm M, Mellstedt H, et al. High doses of natural α-interferon (α-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1984; 1:123-30.
10. Ludwig H, Cohen AM, Huber H, et al. Interferon α-2b with VMCP compared to VMCP alone for induction and interferon α-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer 1991; 27:40-5.
11. Bensinger WI, Buckner CD, Clift RA, et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10:1492-7.
12. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325:1267-73.
13. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
14. Caligaris Cappio F, Cavo M, De Vincentis A, et al. Peripheral blood stem cell transplantion for the treatment of multiple myeloma: biological and clinical implications. Haematologica 1996; 81:356-75.
15. Belch A, Shelley W, Bergsagel D, Wilson K, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57:94-9.
16. Mandelli F, Avvisati G, Amadori G, et al. Maintenance treatment with recombinant interferon α-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322:1430-4.
17. Westin J, Rodjer S, Turesson I, Cortellezzi A, Hjorth M, Zador G. Interferon α-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89:561-8.
18. Browman GP, Bergsagel DE, Sicheri P, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 1995; 13:2354-60.
19. Ludwig H, Cohen AM, Polliak A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6:467-76.
20. Chronic Leukemia-Myeloma Task Force. Proposed guidelines for protocol studies: II. Plasma cell myeloma. Cancer Chemother Rep 1973; 3:145-58.
21. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36:842-54.
22. Bataille R, Durie BGM, Grenier J, Durie GM, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986; 4:80-7.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-582.
24. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
25. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 1984; 53:583-8.
26. Case DC, Lee BJ, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977; 63:897-903.
27. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-6.
28. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983; 10:161-6.
29. Einhorn S, Fernberg JO, Grandér D, Lewenson R. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol 1988; 24:1505-10.
30. Einhorn S, Ahre A, Blomgren H, Joansson B, Mellstedt H, Strander H. Interferon and natural killer activity and clinical response to human interferon-α. Int J Cancer 1982; 30:167-72.
31. Clemens M. Interferons and oncogenes. Nature 1985; 313:531-2.
32. Klein B, Zhang XG, Jourdan M, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytok Net 1990; 1:193-201.
33. Cunningham D, Powels R, Malpas JS, et al. A randomized trial of maintenance therapy with intron-A following high dose melphalan and ABMT in myeloma [abstract]. J Clin Oncol 1993; 12:364.
34. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon-α in treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2405-14.
35. Peest D, Diecher H, Coldewey R, et al. A comparison of polichemotheraphy and melphalan/prednisone for primary remission induction, and interferon-α for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A:146-51.
36. Cooper MR, Dear K, McIntyre OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon α-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993; 11:155-60.
37. Corrado C, Pavlosky S, Saslasky J, Palau V, Santarelli MT. Randomized trial comparing melphalan-prednisone with or without recombinant α2 interferon (rα2 IFN) in multiple myeloma [abstract]. J Clin Oncol 1989; 8:258.
38. Oken MM, Leong T, Kay NE, Greipp PR, Van Ness B, Kyle RA. The effect of adding interferon-α (rIFNα) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial [abstract]. Blood 1995; 86(Suppl 1):441a.
39. Casassus P, Pegourie-Bandelier B, Sadoun A, et al. Randomized comparison of interferon-α with VMCP/VBAP regimen as the induction phase of untreated multiple myeoloma: results of the KIF multicenter trial [abstract]. Blood 1995; 86(Suppl 1):441a.
40. Osterborg A, Bjorkholm M, Bjoreman M, et al. Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from Myeloma Group of Central Sweden. Blood 1993; 81:1428-34.
41. Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A. α2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990; 76:365-8.
42. Patriarca F, Melli C, Damiani D, et al. Plasma cell p170 expression and response to treatment in multiple myeloma. Haematologica 1996; 81:232-7.
43. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13:300-9.
44. Shimizu S, Yoshioka R, Hirose Y, Sugai S, Tachibana J, Konda S. Establishment of two interleukin-6 (B cell stimulatory factor 2/interferon 2) dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989; 169:339-44.
45. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein. IFN-α induced autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147:4402-7.
46. Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 35:543-9.
47. Ludwig CU, Durie BGM, Salmon SE, Moon TE. Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 1983; 19:1625-32.
48. Tanaka H, Tanabe O, Asaoku H, et al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74:1718-22.
49. Osterborg A, Nillson B, Bjorkholm M, Holm G, Mellsted H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 1990; 45:153-6.43
50. The Nordic Myeloma Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Int Med 1996; 124:212-22.
51. Musto P, Sajeva MR, Sanpaolo G, D'Arena G, Scalzulli PR, Carotenuto M. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. Haematologica 1997; 82:354-6
52. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon. Br J Haematol 1996; 94:324-32.